Toxoplasmosis in immunoglobulin M-suppressed mice.
Mice challenged with a pathogenic strain of Toxoplasma gondii develop fatal infections. However, if such mice are initially treated with sulfadiazine (SD), they develop immunity and survive with chronic infections. The role of antibody (Ab) in establishing protective immunity against acute parasitemias and in maintaining chronic infections was investigated using B-cell-deficient (immunoglobulin M-suppressed), T-cell-deficient (athymic), and normal BALB/c mice. All mice not receiving SD treatment rapidly died (mean 7.5 days) after infection, but the majority (80%) of intact mice developed immunity during SD treatment and survived for over 5 months with chronic toxoplasmosis. Athymic mice rapidly died (mean 6.0 days) after the removal of SD treatment. Although all SD-treated immunoglobulin M-suppressed mice eventually died, they lived considerably longer (18 to 83 days) in the complete absence of antitoxoplasma Ab than unprotected mice (7 to 9 days). Histopathological sections of liver, lung, brain, and other tissues showed that toxoplasma organisms gave rise to fatal lesions in all nonsurviving animals. The injection of Ab into acutely infected and athymic mice imparted no protection, but transfer of antitoxoplasma Ab (titer greater than 1:8,000) to immunoglobulin M-suppressed mice after SD treatment resulted in elimination of the parasites in 50% of the mice. Results of this study suggest that Ab may not be decisive in acute infections, but may be important in controlling long-term toxoplasmosis.
D000818:Animals; D000906:Antibodies / Q000276:immunology*; D007116:Immunization, Passive; D007075:Immunoglobulin M; D007165:Immunosuppression Therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D013411:Sulfadiazine / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology*; D014122:Toxoplasma / Q000276:immunology*; D014124:Toxoplasmosis, Animal / Q000276:immunology*
D000906:Antibodies; D007075:Immunoglobulin M; D013411:Sulfadiazine